Cargando…
1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
BACKGROUND: Monoclonal antibodies used in the treatment and prevention of COVID 19 infection are an emerging area of infectious disease. Casirivimab/imdevimab received emergency use authorization (EUA) for the prophylaxis and treatment of COVID 19 disease. Infusion reactions may occur with the admin...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752174/ http://dx.doi.org/10.1093/ofid/ofac492.982 |